Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Feb;3(1 Suppl 1):35–40. doi: 10.1111/j.1365-2125.1976.tb03710.x

Screening procedures in volunteers and patients.

P J Tyrer
PMCID: PMC2958723  PMID: 9957

Full text

PDF
35

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atsmon A., Blum I., Wijsenbeek H., Maoz B., Steiner M., Ziegelman G. The short-term effects of adrenergic-blocking agents in a small group of psychotic patients. Preliminary clinical observations. Psychiatr Neurol Neurochir. 1970 May-Jun;74(3):251–258. [PubMed] [Google Scholar]
  2. BLACKWELL B. HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS. Lancet. 1963 Oct 26;2(7313):849–850. doi: 10.1016/s0140-6736(63)92743-0. [DOI] [PubMed] [Google Scholar]
  3. Blackwell B., Martz B. L. For the first time in man. Clin Pharmacol Ther. 1972 Sep-Oct;13(5):812–826. doi: 10.1002/cpt1972135part2812. [DOI] [PubMed] [Google Scholar]
  4. Bond A. J., Lader M. H. Residual effects of hypnotics. Psychopharmacologia. 1972;25(2):117–132. doi: 10.1007/BF00423189. [DOI] [PubMed] [Google Scholar]
  5. Bond A. J., Lader M. H. The residual effects of flurazepam. Psychopharmacologia. 1973 Sep 28;32(3):223–235. doi: 10.1007/BF00422145. [DOI] [PubMed] [Google Scholar]
  6. Coltart D. J., Shand D. G. Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man. Br Med J. 1970 Sep 26;3(5725):731–734. doi: 10.1136/bmj.3.5725.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. DiMascio A., Shader R. I. Drug administration schedules. Curr Psychiatr Ther. 1971;11:94–99. [PubMed] [Google Scholar]
  8. Granville-Grossman K. L., Turner P. The effect of propranolol on anxiety. Lancet. 1966 Apr 9;1(7441):788–790. doi: 10.1016/s0140-6736(66)91863-0. [DOI] [PubMed] [Google Scholar]
  9. HOLLISTER L. E., KANTER S. L., WRIGHT A. COMPARISON OF INTRAMUSCULAR AND ORAL ADMINISTRATION OF CHLORPROMAZINE AND THIORIDAZINE. Arch Int Pharmacodyn Ther. 1963 Aug 2;144:571–578. [PubMed] [Google Scholar]
  10. HOLLISTER L. E., MOTZENBECKER F. P., DEGAN R. O. Withdrawal reactions from chlordiazepoxide ("Librium"). Psychopharmacologia. 1961 Feb 20;2:63–68. doi: 10.1007/BF00429621. [DOI] [PubMed] [Google Scholar]
  11. HOLLISTER L. E. Studies of delayed-action medication. I. Meprobamate administered as compressed tablets and as two delayed-action capsules. N Engl J Med. 1962 Feb 8;266:281–283. doi: 10.1056/NEJM196202082660604. [DOI] [PubMed] [Google Scholar]
  12. Hollister L. E. Prediction of therapeutic uses of psychotherapeutic drugs from experiences with normal volunteers. Clin Pharmacol Ther. 1972 Sep-Oct;13(5):803–808. doi: 10.1002/cpt1972135part2803. [DOI] [PubMed] [Google Scholar]
  13. Howe R., Shanks R. G. Optical isomers of propranolol. Nature. 1966 Jun 25;210(5043):1336–1338. doi: 10.1038/2101336a0. [DOI] [PubMed] [Google Scholar]
  14. Lader M. H., Tyrer P. J. Central and peripheral effects of propranolol and sotalol in normal human subjects. Br J Pharmacol. 1972 Jul;45(3):557–560. doi: 10.1111/j.1476-5381.1972.tb08113.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Malpas A., Rowan A. J., Boyce C. R., Scott D. F. Persistent behavioural and electroencephalographic changes after single doses of nitrazepam and amylobarbitone sodium. Br Med J. 1970 Jun 27;2(5712):762–764. doi: 10.1136/bmj.2.5712.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Oates J. A. A scientific rationale for choosing patients rather than normal subjects for Phase I studies. Clin Pharmacol Ther. 1972 Sep-Oct;13(5):809–811. doi: 10.1002/cpt1972135part2809. [DOI] [PubMed] [Google Scholar]
  17. Oswald I., Lewis S. A., Dunleavy D. L., Brezinova V., Briggs M. Drugs of dependence though not of abuse: fenfluramine and imipramine. Br Med J. 1971 Jul 10;3(5766):70–73. doi: 10.1136/bmj.3.5766.70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Steiner M., Latz A., Blum I., Atsmon A., Wijsenbeek H. Propranolol versus chlorpromazine in the treatment of psychoses associated with childbearing. Psychiatr Neurol Neurochir. 1973 Nov-Dec;76(6):421–426. [PubMed] [Google Scholar]
  19. Stephen S. A. Unwanted effects of propranolol. Am J Cardiol. 1966 Sep;18(3):463–472. doi: 10.1016/0002-9149(66)90071-3. [DOI] [PubMed] [Google Scholar]
  20. Tyrer P. J., Lader M. H. Effects of beta adrenergic blockade with sotalol in chronic anxiety. Clin Pharmacol Ther. 1973 May-Jun;14(3):418–426. doi: 10.1002/cpt1973143418. [DOI] [PubMed] [Google Scholar]
  21. Tyrer P. J., Lader M. H. Physiological and psychological effects of ±-propranolol, +-propranolol and diazepam in induced anxiety. Br J Clin Pharmacol. 1974 Oct;1(5):379–385. doi: 10.1111/j.1365-2125.1974.tb00273.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tyrer P. J., Lader M. H. Response to propranolol and diazepam in somatic and psychic anxiety. Br Med J. 1974 Apr 6;2(5909):14–16. doi: 10.1136/bmj.2.5909.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tyrer T. P. Are monoamine-oxidase inhibitors antidepressants? Proc R Soc Med. 1973 Sep;66(9):950–951. doi: 10.1177/003591577306600961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wheatley D. Comparative effects of propranolol and chlordiazepoxide in anxiety states. Br J Psychiatry. 1969 Dec;115(529):1411–1412. doi: 10.1192/bjp.115.529.1411. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES